; The overall goal of the Functional Genomics/Genomic Sequencing Core (FGC) is to provide state-of-the-art instruments, and expert scientific and technical advice in cancer genomics to COHCCC investigators. The FGC is equipped with major genomics instrumentation such as Affymetrix GeneChip? Analysis System, Agilent scanner/microarray system, Roche NimbleGen MS200 microarray scanner/system, lllumina HiScanSQ, HiSeq2000, GA llx and Roche 454 FLX. The core also has a next-generation ABI Taqman Realtime PCR system ViiA 7 for microarray validation. FGC provides comprehensive genomic support including transcriptomic and mlRNA/smRNA profiling by,microarrays and RNA-Seq/smRNA-Seq, ChlP-Chip/ChlPSeq, DNA methylation, DNA-Seq including whole genome and target genome sequencing, microarray genome-wide and custom genotyping, SNP/CNV, aCGH, RNAi and qRT-PCR. The FGC has recently set up numerous new genomic technologies and assays including microarray-coupled genome-wide gene expression profiling using difficult clinical formalin-fixed paraffin-embedded (FFPE) RNA samples, smRNASeq and RNA-Seq using FFPE-derived samples, microfluidic chip- and microarray-coupled single-cell genome-wide gene expression profiling. In addition, the FGC has implemented NimbleGen array-based comprehensive high-throughput arrays for relative methylation (CHARM), Affymetrix DMET and genomewide human SNP 6.0 array genotyping, and lllumina Infinium HumanMethylation450 BeadChip that interrogates more than 450,000 methylation sites across the whole human genome at single-nucleotide resolution. The FGC has supported numerous NIH/NCI projects resulting in high impact publications. In summary, the advanced genomic tools in the FGC allow COHCCC investigators to: 1) identify cancer gene mutations at high-throughput rates;2) map cancer genomic, transcriptomic and epigenomic fingerprints to identify genomic biomarkers for cancer early detection and diagnosis;3) identify novel therapeutic targets against cancers;and 4) predict responses to therapy.

Public Health Relevance

The overall goal of the Functional Genomics Core facility is to provide state-of-the-art instruments, scientific and technical advice in cancer genomics. These allow us to potentially identify markers for cancer early detection and the novel targets for cancer therapy. This goal enhances the Cancer Center's dedication to developing innovative new disease-fighting strategies in the battle against cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-30
Application #
8450537
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-08-01
Project End
2017-11-30
Budget Start
2013-04-25
Budget End
2013-11-30
Support Year
30
Fiscal Year
2013
Total Cost
$255,379
Indirect Cost
$103,368
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Salhotra, A; Tsai, N; Thomas, S H et al. (2015) Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50:139-41
Ali, H; Palmer, J; Eroglu, Z et al. (2015) Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus. Bone Marrow Transplant 50:307-9
Yang, Lixin; Perez, Aldwin Apollo; Fujie, Sayuri et al. (2014) Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14:124
Behrendt, Carolyn E; Hurria, Arti; Tumyan, Lusine et al. (2014) Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. J Natl Compr Canc Netw 12:1579-85
Chen, Shiuan; Zhou, Dujin; Hsin, Li-Yu et al. (2014) AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci 139:198-209
Gillis, Peter A; Hernandez-Alvarado, Nelmary; Gnanandarajah, Josephine S et al. (2014) Development of a novel, guinea pig-specific IFN-? ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine. Vaccine 32:3963-70
Sun, Virginia; Grant, Marcia; McMullen, Carmit K et al. (2014) From diagnosis through survivorship: health-care experiences of colorectal cancer survivors with ostomies. Support Care Cancer 22:1563-70
Bhatia, Smita; Landier, Wendy; Hageman, Lindsey et al. (2014) 6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 124:2345-53

Showing the most recent 10 out of 912 publications